Boston Scientific Corp (BSX)
Boston Scientific Corp (BSX) carries a ŷRobot AI score of 80 out of 100. The model's fair value estimate is $48.28, 16.1% above the last close of $41.58. The chart signal reads Hold.
| Metric | BSX |
|---|---|
| AI score | 80 / 100 |
| Chart signal | Hold |
| Fair value estimate | $48.28 |
| Upside to fair value | 16.1% |
| Previous close | $41.58 |
| P/E | 17.74 |
| Price / sales | 2.99 |
| Market cap | $61.45B |
| EPS | 2.46 |
| Revenue growth | 15.5% |
| 1-year price change | 2.5% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about BSX
Is BSX overvalued or undervalued right now?
As of Oct 8, 2026, ŷRobot's fair-value model estimates Boston Scientific Corp (BSX) at $48.28 against a last close of $41.58, implying 16.1% upside to the model's estimate.
Is BSX's chart signal bullish or bearish?
The chart-signal model classifies BSX as Neutral as of Oct 8, 2026, with a signal score of 0.08 on a -1 to 1 scale.
What is BSX's ŷRobot AI score?
BSX scores 80 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 8, 2026.
Is BSX stock expensive on P/E and P/S?
BSX trades at 17.7 times earnings and 3.0 times sales as of Oct 8, 2026.
What does BSX's seasonal forecast show?
ŷRobot's seasonal forecast curve for BSX reads -1.2% at 30 days, +0.0% at 90 days, and +2.5% at one year as of Oct 8, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is BSX growing?
Boston Scientific Corp's revenue growth is +15.5% and free-cash-flow growth is +4.1% on the latest reported figures.
BSX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.